Two new studies have found that new adjuvant treatments for breast cancer are cost-effective at improving survival.
Published in the August 1, 2007 issue of Cancer, a journal of the American Cancer Society, the two studies looked at the cost-effectiveness of different drugs for the management of adjuvant therapies for early breast cancer.
In a Canadian economic study of estrogen receptor positive breast cancers, switching from tamoxifen to the oral steroidal aromatase inhibitor exemestane (trade name: Aromasin) enlarged disease free survival at a minimal cost per person.
In another of study of human epidermal growth factor receptor 2 (HER2)-positive breast cancer, the addition of the anti-HER2 receptor monoclonal antibody, trastuzumab (trade name: Herceptin), is projected to improve life expectancy at a comparatively low cost.
Breast cancer is a major cause of cancer mortality, second only to lung cancer as a cause of cancer death in women. The five-year survival rate for localized breast cancer has increased from 80 percent in the 1950s to 98 percent today. As the therapeutic effectiveness of these drugs has been verified and is included in professional treatment guidelines, their cost-effectiveness is being investigated.
Cost-effectiveness is measured not just in life years (LY) gained but is attuned also for the quality of life gained. This combination is expressed as a quality-adjusted life year (QALY). The ratio of cost to QALY is designed to present a quantitative estimate of the cost-effectiveness of a therapy.
A recent study showed that switching from tamoxifen to exemestane after two to three years of tamoxifen considerably improves disease-free survival compared to tamoxifen alone.
Ms. Nancy Risebrough from the Hope Research Centre, Sunnybrook Health Sciences Centre in Toronto and Dr. Nicole Mittmann from the Hope Research Centre at Sunnybrook Health Sciences
Centre in Toronto and the University of Toronto and colleagues evaluated the cost-effectiveness of switching from tamoxifen to exemestane after two to three years.
The authors found that over 7.5 years, a tamoxifen-exemestane adjuvant protocol improved disease free survival (LY and QALY) at an additional cost of 2,889 Can dollar per patient. The incremental cost-effectiveness ratio was calculated to be 24,185 Can dollar/QALY gained, well below a recognized threshold of 50,000 Can dollar /QALY gained.
Based on three-year follow-up of a recent clinical trial, the addition of trastuzumab to adjuvant chemotherapy treatment has been projected to improve considerably the long-term survival of early HER2-positive breast cancers. Dr. Louis Garrison, Jr of the University of Washington in Seattle and co-investigators assessed the cost-effectiveness of adding trastuzumab to standard chemotherapy.
Dr. Garrison and co-authors estimated that life expectancy would get better by three years on average with the addition of this drug due to reduced disease reappearance. Over a lifetime, the cost-effectiveness ratio was estimated to be 26,417 US dollars/QALY and over 20 years was estimated at 34,201 US dollars.
The two economic studies agree with earlier cost-effectiveness studies of the similar regimens and support their clinical use. The cost-effectiveness ratios calculated for both exemestane and trastuzumab were below those of many widely used oncology treatments. Related medicine news :1
. Surgery and Adjuvant Therapy Can Work for Pancreatic Cancer2
. Bird-flu Vaccine Adjuvant Contract Goes to Novartis3
. Consensus on "Combination Therapy" for Breast Cancer
. Breast cancer treatment to be determined by gene test5
. Breast Feeding prevents obesity later on in life6
. Breast milk is essential7
. Breast Cancer Surgery Causes Psychological problems 8
. Breast cancer evidence9
. Letrozole Beats Tamoxifen in Breast Cancer Therapy10
. Breast screening among diabetic women11
. Breast feeding can alter hormones